Eton Pharmaceuticals (ETON) CBO David Krempa Exercises Options, Sells 25k

What Happened
David Krempa, Chief Business Officer of Eton Pharmaceuticals (ETON), exercised 25,000 stock options on 2026-08-24 at an exercise price of $7.31 per share (cost $182,750) and sold 25,000 shares the same day in the open market for a weighted average price of $65.07 per share (gross proceeds $1,626,750). The filing also shows a derivative disposition reported at $0, which reflects the option being surrendered/converted in the exercise process.

Key Details

• Transaction date: 2026-08-24 (filed same day).
• Exercise: 25,000 shares acquired at $7.31 each — total cash paid $182,750.
• Sale: 25,000 shares disposed at a weighted average $65.07 — total proceeds $1,626,750.
• Reported sale price range: $64.88 to $65.57 (sales occurred in multiple trades; weighted average reported per footnote).
• Vesting: the option granted 2/20/2019 vested in 48 equal monthly installments (footnote).
• Derivative reporting: a separate derivative line shows a $0 disposal (reflects the option being exercised/surrendered).
• Shares owned after transaction: not specified in the provided excerpt.
• Footnote: full per-trade price/quantity details are available upon request to the SEC/issuer/security holders (footnote).
• Filing timeliness: filed the same day as the transactions (no late filing indicated).
• Remarks: the form was filed on the reporting person's behalf by an authorized designee.

Context
This was an option exercise followed by an immediate sale (a cashless-style transaction), a common way for insiders to monetize vested options. The sale converts the economic value of the exercised options into cash; it is a factual disclosure of insider activity and does not, by itself, indicate the insider’s long-term view of the company.